Dual targeting of lipid metabolic reprogramming and immunosuppressive sentinel lymph nodes potentiates anti-metastatic therapy for triple negative breast cancer
Source abstract
Abstract
Inducing immunogenic cell death (ICD) in cancer cells provides a promising approach in immunotherapy, however, oxidative stress relief and metabolic plasticity enhancement limit the immune-stimulating effect of traditional ICD inducer in sentinel lymph nodes (SLN), owing to the metabolism of fatty acids. In this article, a biocompatible green liposome CL-Lip was designed to not only selectively induce ICD in primary and metastatic 4T1 cells, but also relieved the immunosuppression in invasive SLN. CL-Lip is composed of engineered liposomes modified with linoleic acid and catalase, which synergistically trigger ICD, stimulate lipid peroxidation, PD-L1 carbonylation and effectively promote the maturation of dendritic cells and T cell differentiation. Moreover, catalase also downregulated the hypoxia level in SLN. Through cellular experiments and transcriptome analysis, it is proved that the ICD induction via CL-Lip is mediated by ROS generation, resulting from the YAP-dependent fatty acid oxidation (FAO) interference. Transcriptome analysis revealed that engineered CL-Lip diminishes YAP-dependent FAO pathway and effectively antagonizes the metabolic flexibility, thereby selectively triggering the metabolic dead-associated ICD process in both primary and metastatic 4T1 cells. In animal experiments, this little reported metabolic-driven ICD route not only significantly reduces metastatic foci, but also induces a “cold-to-hot” remodeling of SLN, resulting in the formation of a in situ tumor vaccine. These findings hold great significance for the development of next-generation ICD inducers and immunotherapy approaches. • Lipid metabolic reprogramming caused by CL-Lip selectively triggers immunogenic cell death in 4T1 cells. • Engineered CL-Lip are of good biocompatibility and significant immune-activation effect. • Sentinel lymph nodes are protected from invasion. • Tumor proliferation and metastasis were inhibited.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cancer, Lipids, and Metabolism · Cancer, Hypoxia, and Metabolism · Metabolomics and Mass Spectrometry Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients10.1038/s41467-022-34581-2 ↗
2. Toward a more precise future for oncology10.1016/j.ccell.2020.03.014 ↗
3. Engineering hybrid nanoparticles for targeted codelivery of triptolide and CYP3A4 siRNA against pulmonary metastatic melanoma10.1126/sciadv.adv6990 ↗
4. Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes10.1016/j.cell.2023.02.021 ↗
5. Seizing the fate of lymph nodes in immunotherapy: to preserve or not?10.1016/j.canlet.2024.216740 ↗
6. Activating iterative revolutions of the cancer-immunity cycle in hypoxic tumors with a smart nano-regulator10.1002/adma.202400196 ↗
7. Dismantlable coronated nanoparticles for coupling the induction and perception of immunogenic cell death10.1002/adma.202313097 ↗
8. Immunogenic cell death in cancer therapy10.1146/annurev-immunol-032712-100008 ↗
9. Inflammation – a new therapeutic target in pneumonia10.1159/000084039 ↗
10. Calming cytokine storm in pneumonia by targeted delivery of TPCA-1 using platelet-derived extracellular vesicles10.1016/j.matt.2020.05.017 ↗
11. Can single-cell biology realize the promise of precision medicine?10.1038/s41587-024-02138-x ↗
12. Precise regulation of inflammation and immunosuppressive microenvironment for amplified photothermal/immunotherapy against tumour recurrence and metastasis10.1016/j.nantod.2021.101266 ↗
13. Nano drug delivery systems for advanced immune checkpoint blockade therapy10.7150/thno.112475 ↗
14. Dendritic nanomedicine enhances chemo-immunotherapy by disturbing metabolism of cancer-associated fibroblasts for deep penetration and activating function of immune cells10.1016/j.apsb.2024.03.010 ↗
15. Impairing tumor metabolic plasticity via a stable metal-phenolic-based polymeric nanomedicine to suppress colorectal cancer10.1002/adma.202300548 ↗
16. Regulation of protein conformation enables cell-selective targeting of virus-mimicking nanoparticles for siRNA therapy of glioblastoma10.1002/adma.202401640 ↗
17. Combined single-cell and spatial transcriptomics reveal the metabolic evolvement of breast cancer during early dissemination10.1002/advs.202205395 ↗
18. Hippo-YAP/TAZ signalling coordinates adipose plasticity and energy balance by uncoupling leptin expression from fat mass10.1038/s42255-024-01045-4 ↗
19. Single-cell transcriptome analysis indicates fatty acid metabolism-mediated metastasis and immunosuppression in male breast cancer10.1038/s41467-023-41318-2 ↗
20. Tumor metastasis to lymph nodes requires YAP-dependent metablic adaption10.1126/science.aav0173 ↗
21. Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation10.1038/s41467-019-10592-4 ↗
22. Lymph protects metastasizing melanoma cells from ferroptosis10.1038/s41586-020-2623-z ↗
23. Multi-enzyme co-expressed nanomedicine for anti-metastasis tumor therapy by up-regulating cellular oxidative stress and depleting cholesterol10.1002/adma.202307752 ↗
24. Removal of ferroptosis barrier mediated by nanoengineering platform for the treatment of tumor lymphatic metastasis
25. YWHAG deficiency disrupts the EMT-associated network to induce oxidative cell death and prevent metastasis10.1002/advs.202301714 ↗
26. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
27. Oxidative stress in cancer10.1016/j.ccell.2020.06.001 ↗
28. Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress10.1016/j.cmet.2020.06.002 ↗
29. Nanoparticle elasticity regulates phagocytosis and cancer cell uptake10.1126/sciadv.aaz4316 ↗
30. Fastp: an ultra-fast all-in-one FASTQ preprocessor10.1093/bioinformatics/bty560 ↗
31. HISAT: a fast spliced aligner with low memory requirements10.1038/nmeth.3317 ↗
32. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads10.1038/nbt.3122 ↗
33. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome10.1186/1471-2105-12-323 ↗
34. Systemic targeting of lymph node metastases through the blood vascular system by using size-controlled nanocarriers10.1021/nn5070259 ↗
35. Interplay between liposomes and IgM: principles, challenges, and opportunities10.1002/advs.202301777 ↗
36. Catalase-loaded cisplatin-prodrug-constructed liposomes to overcome tumor hypoxia for enhanced chemo-radiotherapy of cancer10.1016/j.biomaterials.2017.05.025 ↗
37. Liposome-supported enzymatic peritoneal dialysis10.1016/j.biomaterials.2017.08.016 ↗
38. Cholesterol-based anionic long-circulating cisplatin liposomes with reduced renal toxicity10.1016/j.biomaterials.2011.10.081 ↗
39. Metabolic-Pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets10.1016/j.cmet.2020.10.012 ↗
40. Defining the landscape of metabolic dysregulations in cancer metastasis10.1007/s10585-021-10140-9 ↗
41. Liposome composition in drug delivery design, synthesis, characterization, and clinical application10.1016/j.addr.2021.113851 ↗
42. γ-Linolenic acid and eicosapentaenoic acid induce modi'cations in mitochondrial metabolism, reactive oxygen species generation, lipid peroxidation and apoptosis in Walker 256 rat carcinosarcoma cells10.1016/S1388-1981(01)00136-6 ↗
43. Targeted solvatochromic fluorescent probes for imaging lipid order in organelles under oxidative and mechanical stress10.1021/jacs.0c10972 ↗
44. Phosphorylation of eukaryotic initiation factor-2α (eIF2α) in autophagy10.1038/s41419-020-2642-6 ↗
45. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours10.1038/s41551-019-0375-6 ↗
46. Redox homeostasis maintained by GPX4 facilitates STING activation10.1038/s41590-020-0699-0 ↗
47. Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity10.1038/s43018-023-00522-1 ↗
48. Don't eat me/eat me signals as a novel strategy in cancer immunotherapy10.1016/j.heliyon.2023.e20507 ↗
49. Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment10.1021/nn504025a ↗
50. ATP-exhausted nanocomplexes for intratumoral metabolic intervention and photoimmunotherapy10.1016/j.biomaterials.2022.121503 ↗
51. Yes-associated protein (YAP) binds to HIF-1alpha and sustains HIF-1alpha protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress10.1186/s13046-018-0892-2 ↗
52. Single-atom nanozyme with asymmetric electron distribution for tumor catalytic therapy by disrupting tumor redox and energy metabolism homeostasis10.1002/adma.202208512 ↗
53. Metabolic homeostasis-regulated nanoparticles for antibody-independent cancer radio-immunotherapy10.1002/adma.202207343 ↗
54. Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments10.1038/s41467-022-32066-w ↗
55. Dual role of oxygen during lipoxygenase reactions10.1111/j.1742-4658.2005.04673.x ↗
56. 'Enzymatic' lipid peroxidation: reactions of mammalian lipoxygennases10.1016/0891-5849(91)90008-Q ↗
57. Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing10.1038/s41556-020-0477-0 ↗
58. YAP/TAZ upstream signals and downstream responses10.1038/s41556-018-0142-z ↗
59. Artificial natural killer cells for specific tumor inhibition and renegade macrophage re-education10.1002/adma.201904495 ↗
60. Unraveling the complex interplay between T cell metabolism and function10.1146/annurev-immunol-042617-053019 ↗
61. Trojan horse-like nano-AIE aggregates based on homologous targeting strategy and their photodynamic therapy in anticancer application10.1002/advs.202102561 ↗
62. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy10.1038/s41591-023-02234-6 ↗